Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

Denali to advance lead Parkinson’s program, BBB-penetrant candidates with cash infusion from Biogen

With more than $1 billion in upfront money via its biggest deal yet, Denali now has enough firepower to bring its lead program into late-stage testing and validate its CNS delivery technology in the clinic.

The deal with Biogen Inc. (NASDAQ:BIIB) also helps Denali Therapeutics Inc. (NASDAQ:DNLI) derive value from its Transport Vehicle (TV) technology in areas where it wasn’t planning to invest.

The agreement's cash and equity upfront payment brings the company’s cash position to a little

Read the full 777 word article

How to gain access

Continue reading with a
two-week free trial.